ViewsML’s AI-Powered Virtual Biomarker Staining Research to be Presented at American Association for Cancer Research Drug Discovery and Development Conference 2026 (AACR D3)
Princess Margaret Cancer Centre’s Dr. Charles Jeffrey Tan to present findings on diagnostic accuracy of virtual PD-L1 immunohistochemistry in head and neck squamous cell carcinoma in collaboration with ViewsML
WHO: ViewsML, a leader in AI-powered virtual biomarker staining, will attend the American Association for Cancer Research (AACR) Drug Discovery and Development (AACR D3) conference. ViewsML partnered with Dr. Charles Jeffrey Tan of the University Health Network's Princess Margaret Cancer Centre to contribute data to a scientific poster presentation, alongside co-authors Dr. Lilian Siu and Dr. Anna Spreafico.
WHAT: ViewsML contributed data to the poster "Diagnostic Accuracy of Virtual Programmed Death Ligand-1 Immunohistochemistry in Head and Neck Squamous Cell Carcinoma using Artificial Intelligence." The research will be presented during Poster Session A.
Virtual biomarker staining has the potential to transform cancer research and precision medicine by enabling biomarker analysis directly from standard H&E pathology images within existing workflows. By reducing reliance on additional tissue sections and laboratory staining, AI-powered computational approaches can help preserve limited tissue samples, accelerate research workflows, and expand access to advanced biomarker insights. ViewsML's contribution to this research reflects its commitment to advancing AI-driven pathology tools that support oncology drug discovery and development.
WHERE:
AACR Drug Discovery and Development (AACR D3)
Sheraton Boston Hotel
Boston, Massachusetts
Registration
Members of the media, researchers, and conference attendees interested in learning more about ViewsML's virtual biomarker staining technology are encouraged to schedule a meeting with the team during the conference here or by contacting pr@viewsml.com.
WHEN: The conference will take place July 21–24, 2026.
Poster Session A:
Wednesday, July 22, 2026
6:15–8:45 p.m. ET
About ViewsML
ViewsML is transforming pathology by unlocking the full biological value of H&E slides through AI-driven virtual staining of biomarkers. Designed to integrate seamlessly into existing pathology workflows, ViewsML's platform virtually predicts biomarker expression from standard H&E slides, preserving scarce tissue samples and delivering immunohistochemistry-equivalent results in minutes, without additional lab steps — accelerating research, clinical trials, and patient care. ViewsML is building the world's first virtual biomarker library, enabling scientists and clinicians to perform virtual staining in minutes rather than the days to weeks required by traditional laboratory methods.
Learn more at ViewsML.
Contact
Public Relations and Marketing Communications
pr@viewsml.com